Bladder cancer: Current management and opportunities for a personalized approach

Mount Sinai Journal of Medicine

Volumn 77, Issue 6, 2010, Pages 587-596

  Galsky, Matthew D ^a   Hall, Simon J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

bladder cancer; muscle invasive; non muscle invasive; personalized medicine; urothelial carcinoma

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; LAPATINIB; METHOTREXATE; PACLITAXEL; PEMETREXED; SUNITINIB; TRASTUZUMAB; VINBLASTINE;

BASEMENT MEMBRANE; BLADDER CANCER; BLADDER CARCINOGENESIS; BLOOD TOXICITY; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL TRIAL; CYSTECTOMY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEBRILE NEUTROPENIA; GENE OVEREXPRESSION; HEARING LOSS; HUMAN; KIDNEY DISEASE; LAMINA PROPRIA; LYMPH NODE DISSECTION; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PELVIS LYMPH NODE; PERIPHERAL NEUROPATHY; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; TRANSURETHRAL RESECTION;

ANTINEOPLASTIC AGENTS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; TUMOR MARKERS, BIOLOGICAL; URETHRAL NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 78649666335     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20224     Document Type: Review

References (59)

1. Jemal A, Siegel R, Xu J, et al., Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Mitra AP, Datar RH, Cote RJ., Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006; 24: 5552-5564.
3. Iyer G, Lin O, Al-Ahmadie H, et al., Identification and characterization of FGFR3 mutations in high-grade bladder cancer. ASCO Genitourinary Cancers Symposium 2010: Abstract 296.
4. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al., Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009; 23: 675-680.
5. Avritscher EB, Cooksley CD, Grossman HB, et al., Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006; 68: 549-553.
6. Lamm DL., Carcinoma in situ. Urol Clin North Am 1992; 19: 499-508.
7. Anderström C, Johansson S, Nilsson S., The significance of lamina propria invasion on the prognosis of patients with bladder tumors. J Urol 1980; 124: 23-26.
8. Shahin O, Thalmann GN, Rentsch C, et al., A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003; 169: 96-100.
9. Karam J, Shah J, Kader AK, et al., Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. ASCO Genitourinary Cancers Symposium 2010: Abstract 275.
10. Stein JP, Lieskovsky G, Cote R, et al., Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-675.
11. Grossman HB, Natale RB, Tangen CM, et al., Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-866.
12. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International Collaboration of Trialists [published correction appears in Lancet 1999;354:1650]. Lancet 1999; 354: 533-540.
13. Hall RR., Updated results of a randomized controlled trial of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer. Proc Am Soc Clin Oncol 2002; 21:Abstract 710.
14. David KA, Milowsky MI, Ritchey J, et al., Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 2007; 178: 451-454.
15. Bochner BH, Kattan MW, Vora KC., Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006; 24: 3967-3972.
16. Shariat SF, Svatek RS, Tilki D, et al., International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 2010; 105: 1402-1412.
17. Als AB, Dyrskjøt L, von der Maase H, et al., Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007; 13 (15 part 1): 4407-4414.
18. Sanchez-Carbayo M, Socci ND, Lozano J, et al., Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006; 24: 778-789.
19. Mitra AP, Pagliarulo V, Yang D, et al., Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol 2009; 27: 3929-3937.
20. Karam JA, Lotan Y, Karakiewicz PI, et al., Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007; 8: 128-136.
21. Shariat SF, Tokunaga H, Zhou J, et al., p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004; 22: 1014-1024.
22. Michaelson MD, Shipley WU, Heney NM, et al., Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder. Br J Cancer 2004; 90: 578-581.
23. Sternberg CN, Yagoda A, Scher HI, et al., Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985; 133: 403-407.
24. Von der Maase H, Hansen SW, Roberts JT, et al., Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077.
25. Bellmunt J, von der Maase H, Mead GM, et al., Randomized phase III study comparing paclitaxel/ cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC30987/ Intergroup Study. Proc Am Soc Clin Oncol 2007; 25:Abstract 5030.
26. Bellmunt J, von der Maase H, Theodore C, et al., Randomised phase III trial of vinflunine plus best supportive care vs best supportive care alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium. J Clin Oncol 2008; 26 (suppl 15S):Abstract 5028.
27. Ciardiello F, Caputo R, Bianco R, et al., Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063.
28. Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, et al., Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 2010; 105: 317-321.
29. McConkey DJ, Choi W, Marquis L, et al., Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009; 28: 335-344.
30. Gallagher DJ, Milowsky MI, Gerst SR, et al., Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010; 28: 1373-1379.
31. Sonpavde G, Jian W, Liu H, et al., Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009; 27: 391-399.
32. Galsky MD, Sonpavde G, Hellerstedt BA, et al., Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma. ASCO Genitourinary Cancers Symposium 2010: Abstract 276.
33. Hahn NM, Stadler WM, Zon RT, et al., A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU-0475. J Clin Oncol 2009; 27 (suppl 15S):Abstract 5018.
34. Esrig D, Elmajian D, Groshen S, et al., Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 1259-1264.
35. Cote RJ, Esrig D, Groshen S, et al., p53 and treatment of bladder cancer. Nature 1997; 385: 123-125.
36. Stadler WM, Lerner SP, Groshen S, et al., Randomized trial of p53 targeted adjuvant therapy for patients with organ-confined node-negative urothelial bladder cancer. J Clin Oncol 2009; 27 (suppl 15S):Abstract 5017.
37. Bellmunt J, Paz-Ares L, Cuello M, et al., Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007; 18: 522-528.
38. Takata R, Katagiri T, Kanehira M, et al., Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci 2007; 98: 113-117.
39. Takata R, Katagiri T, Kanehira M, et al., Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005; 11: 2625-2636.
40. Williams PD, Cheon S, Havaleshko DM, et al., Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res 2009; 69: 8302-8309.
41. Wülfing C, Machiels JP, Richel DJ, et al., A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009; 115: 2881-2890.
42. Galsky MD, Zaks T, Hassani H, et al., Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Invest New Drugs 2010; 28: 194-198.
43. Galsky MD, Von Hoff DD, Neubauer M, et al., Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. J Clin Oncol 2009; 27 (suppl 15S):Abstract 3541.
44. Pruthi RS, Nielsen M, Heathcote S, et al., A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int 2010; 106: 349-356.
45. Levitt JM, Yamashita H, Jian W, et al., Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Mol Cancer Ther 2010; 9: 1128-1135.
46. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al., A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10: 1066-1073.
47. Logothetis CJ, Dexeus FH, Finn L, et al., A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8: 1050-1055.
48. Siefker-Radtke AO, Millikan RE, Tu SM, et al., Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002; 20: 1361-1367.
49. Sternberg CN, de Mulder PH, Schornagel JH, et al., Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001; 19: 2638-2646.
50. Bamias A, Aravantinos G, Deliveliotis C, et al., Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004; 22: 220-228.
51. Dreicer R, Manola J, Roth BJ, et al., Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004; 100: 1639-1645.
52. Vaughn DJ, Broome CM, Hussain M, et al., Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20: 937-940.
53. McCaffrey JA, Hilton S, Mazumdar M, et al., Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15: 1853-1857. (Pubitemid 27209514)
54. Witte RS, Elson P, Bono B, et al., Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997; 15: 589-593.
55. Lorusso V, Pollera CF, Antimi M, et al., A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998; 34: 1208-1212.
56. Vaishampayan UN, Faulkner JR, Small EJ, et al., Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer 2005; 104: 1627-1632.
57. Culine S, Theodore C, De Santis M, et al., A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006; 94: 1395-1401.
58. Galsky MD, Mironov S, Iasonos A, et al., Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007; 25: 265-270.
59. Sweeney CJ, Roth BJ, Kabbinavar FF, et al., Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006; 24: 3451-3457.